{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:11:03Z","timestamp":1793653863719,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01867-y","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:03:08Z","timestamp":1784977388000},"page":"4305-4324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5171-9854","authenticated-orcid":false,"given":"Paola","family":"Facheris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4009-0544","authenticated-orcid":false,"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8710","authenticated-orcid":false,"given":"Carlo A.","family":"Vignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"2","key":"1867_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1867_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"18","key":"1867_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"10246","key":"1867_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"10387","key":"1867_CR5","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"1","key":"1867_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1867_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamadermatol.2024.3696","volume":"160","author":"AS Paller","year":"2024","unstructured":"Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, et al. Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks. JAMA Dermatol. 2024;160(12):1304\u201313.","journal-title":"JAMA Dermatol"},{"issue":"10290","key":"1867_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"10348","key":"1867_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"5","key":"1867_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1867_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1867_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"issue":"18","key":"1867_CR13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"1867_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1867_CR15","doi-asserted-by":"publisher","first-page":"2665961","DOI":"10.1080\/09546634.2026.2665961","volume":"37","author":"EL Simpson","year":"2026","unstructured":"Simpson EL, Prajapati VH, Bunick CG, Chovatiya R, Gold LFS, Figueras Nart I, et al. Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. J Dermatolog Treat. 2026;37(1):2665961.","journal-title":"J Dermatolog Treat"},{"key":"1867_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20674","author":"LF van der Gang","year":"2025","unstructured":"van der Gang LF, Atash K, Zuithoff NPA, Haeck I, Boesjes CM, Baco\u015f-Cosma OI, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20674.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1867_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07.019","volume":"154","author":"SY Tsai","year":"2024","unstructured":"Tsai SY, Phipatanakul W, Hawryluk EB, Oyoshi MK, Schneider LC, Ma KS. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: a population-based cohort study. J Allergy Clin Immunol. 2024;154(5):1195-203.e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1867_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1867_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/bjd\/ljad229","volume":"189","author":"C Ertus","year":"2023","unstructured":"Ertus C, Scailteux LM, Lescoat A, Berthe P, Auffret V, Dupuy A, et al. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis. Br J Dermatol. 2023;189(4):368\u201380.","journal-title":"Br J Dermatol"},{"key":"1867_CR20","doi-asserted-by":"publisher","first-page":"1342810","DOI":"10.3389\/fimmu.2024.1342810","volume":"15","author":"Q He","year":"2024","unstructured":"He Q, Xie X, Chen Q, Li W, Song Z, Wang X, et al. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses. Front Immunol. 2024;15:1342810.","journal-title":"Front Immunol"},{"issue":"1","key":"1867_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","volume":"160","author":"JP Ingrassia","year":"2024","unstructured":"Ingrassia JP, Maqsood MH, Gelfand JM, Weber BN, Bangalore S, Lo Sicco KI, et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 2024;160(1):28\u201336.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1867_CR22","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2022;78(12):1923\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1867_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40257-025-00932-0","volume":"26","author":"B King","year":"2025","unstructured":"King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, et al. Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3 years and up to 4 years of treatment. Am J Clin Dermatol. 2025;26(4):611\u201322.","journal-title":"Am J Clin Dermatol"},{"key":"1867_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19090","author":"A Sechi","year":"2023","unstructured":"Sechi A, Song J, Dell\u2019Antonia M, Heidemeyer K, Piraccini BM, Starace M, et al. Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19090.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1867_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70172","author":"CG Bunick","year":"2025","unstructured":"Bunick CG, Irvine AD, Silverberg JI, Guttman-Yassky E, Shahriari M, Gao X, et al. Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70172.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1867_CR26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s12325-023-02445-w","volume":"40","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, et al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv Ther. 2023;40(4):1867\u201383.","journal-title":"Adv Ther"},{"key":"1867_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00997-x","author":"ATM R\u00f8nnstad","year":"2025","unstructured":"R\u00f8nnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen ML, Alinaghi F, et al. Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and upadacitinib in atopic dermatitis: a systematic review and meta-analysis. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00997-x.","journal-title":"Am J Clin Dermatol"},{"key":"1867_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092953","author":"L Ibba","year":"2025","unstructured":"Ibba L, Falcidia C, Di Giulio S, Bianco M, Valenti M, Facheris P, et al. Real-world effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 52-week retrospective study. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14092953.","journal-title":"J Clin Med"},{"key":"1867_CR29","doi-asserted-by":"publisher","first-page":"adv42990","DOI":"10.2340\/actadv.v105.42990","volume":"105","author":"SC Van Helmond","year":"2025","unstructured":"Van Helmond SC, Willaert M, Nguyen VH, Nijsten T, Waalboer-Spuij R, Hijnen D. Real-world effectiveness and safety of Janus kinase inhibitors in alopecia areata: a retrospective cohort study of 72 patients. Acta Derm Venereol. 2025;105:adv42990.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1867_CR30","doi-asserted-by":"publisher","first-page":"1771776","DOI":"10.1155\/dth\/1771776","volume":"2026","author":"N Perrotta","year":"2026","unstructured":"Perrotta N, Fiorito LA, Vescovo R, Ricupito A, Gemma GPA, Campanale EA, et al. Trichoscopic markers and clinical response patterns with ritlecitinib in severe alopecia areata: 24-week outcomes from a prospective real-world cohort. Dermatol Ther. 2026;2026(1):1771776.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1867_CR31","doi-asserted-by":"publisher","first-page":"103504","DOI":"10.1016\/j.autrev.2023.103504","volume":"23","author":"V Solitano","year":"2024","unstructured":"Solitano V, Facheris P, Petersen M, D\u2019Amico F, Ortoncelli M, Aletaha D, et al. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: an international appropriateness study. Autoimmun Rev. 2024;23(3):103504.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1867_CR32","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"1867_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf144","author":"L Ibba","year":"2025","unstructured":"Ibba L, Gargiulo L, Bianco M, Di Giulio S, Cascio Ingurgio R, Alfano A, et al. Potential role of leptin in jak2 inhibitor-associated weight gain: a monocentric retrospective study. Clin Exp Dermatol. 2025. https:\/\/doi.org\/10.1093\/ced\/llaf144.","journal-title":"Clin Exp Dermatol"},{"key":"1867_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejim.2025.02.021","volume":"134","author":"L Dagna","year":"2025","unstructured":"Dagna L, Alunno A, Farina N, Agnelli G, Borghi C, Caporali R, et al. Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus kinase inhibitors: the JAK-ERA multidisciplinary consensus. Eur J Intern Med. 2025;134:114\u20138.","journal-title":"Eur J Intern Med"},{"issue":"10","key":"1867_CR35","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1093\/rheumatology\/kead211","volume":"62","author":"F Campanaro","year":"2023","unstructured":"Campanaro F, Zaffaroni A, Cacioppo E, Cappelli A, Bert\u00f9 L, Donadini MP, et al. Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis. Rheumatology (Oxford). 2023;62(10):3245\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1867_CR36","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.mayocp.2020.12.035","volume":"96","author":"J Bilal","year":"2021","unstructured":"Bilal J, Riaz IB, Naqvi SAA, Bhattacharjee S, Obert MR, Sadiq M, et al. Janus kinase inhibitors and risk of venous thromboembolism: a systematic review and meta-analysis. Mayo Clin Proc. 2021;96(7):1861\u201373.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1867_CR37","doi-asserted-by":"publisher","first-page":"e0329336","DOI":"10.1371\/journal.pone.0329336","volume":"20","author":"X He","year":"1990","unstructured":"He X, Su J, Wang K, Liang Y, Wang L. Global, regional, and national prevalence and trends of gynecological diseases among women of childbearing age from 1990 to 2021: an analysis of the global burden of disease study 2021. PLoS One. 1990;20(8):e0329336.","journal-title":"PLoS One"},{"issue":"1","key":"1867_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1867_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.70173","author":"L Ibba","year":"2026","unstructured":"Ibba L, Gargiulo L, Bianco M, Di Giulio S, Cascio Ingurgio R, Alfano A, et al. JAK inhibitors and menstrual cycle alterations: insights from a case series of 16 female patients. J Dtsch Dermatol Ges. 2026. https:\/\/doi.org\/10.1111\/ddg.70173.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"1867_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/bjd\/ljad072","volume":"189","author":"J Wan","year":"2023","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Fuxench ZCC, et al. Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023;189(1):53\u201361.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1867_CR41","doi-asserted-by":"publisher","first-page":"e0277469","DOI":"10.1371\/journal.pone.0277469","volume":"17","author":"MM Hedderson","year":"2022","unstructured":"Hedderson MM, Asgari MM, Xu F, Quesenberry CP, Sridhar S, Geier J, et al. Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: a retrospective cohort study. PLoS One. 2022;17(11):e0277469.","journal-title":"PLoS One"},{"key":"1867_CR42","doi-asserted-by":"publisher","first-page":"k1786","DOI":"10.1136\/bmj.k1786","volume":"361","author":"RJ Silverwood","year":"2018","unstructured":"Silverwood RJ, Forbes HJ, Abuabara K, Ascott A, Schmidt M, Schmidt SAJ, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361:k1786.","journal-title":"BMJ"},{"issue":"2","key":"1867_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","volume":"156","author":"L Wang","year":"2020","unstructured":"Wang L, Bierbrier R, Drucker AM, Chan A-W. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):158\u201371.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01867-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:30Z","timestamp":1788981690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01867-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01867-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, Abbvie, and Pfizer. Luigi Gargiulo has been a consultant and\/or speaker and has participated in advisory boards for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Incyte, Galderma, Pierre Fabre, Johnson and Johnson, Novartis, Pfizer, Sanofi, and UCB Pharma. Luciano Ibba served as consultants for Almirall. Mario Valenti has served as consultant\/speaker for Novartis, Almirall, Eli-Lilly, Abbvie, Johnson&Johnson, UCB, Boehringer-Ingelheim, Difa Cooper, Sun-Pharma, Leo Pharma, and Bristol Myers Squibb. Mario Valenti is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Francesco D\u2019Oria, Giulio Foggi, Costanza Falcidia and Carlo A. Vignoli have no conflict of interest to disclose. Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen and Boehringer Ingelheim. Antonio Costanzo has served as an advisory board member, consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme and UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a non-interventional observational study. According to local regulations, formal ethics committee approval and written informed consent were not required. The study was notified to the Italian Medicines Agency (AIFA, Study ID 2805, study code JAKiSafe), and the competent Ethics Committee acknowledged the study. All procedures were conducted in accordance with the Declaration of Helsinki and applicable national regulations.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}